Back to Search
Start Over
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
- Source :
-
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme [Horm Metab Res] 2008 Apr; Vol. 40 (4), pp. 281-5. Date of Electronic Publication: 2008 Feb 15. - Publication Year :
- 2008
-
Abstract
- Risedronate and teriparatide have opposite actions on the osteoblast-osteoclast dipole and are expected to influence the RANK/RANKL/osteoprotegerin (OPG) system. We aimed to evaluate changes in serum OPG and RANKL after risedronate or teriparatide administration in postmenopausal osteoporotic women. Seventy-four postmenopausal Caucasian women (age 64.1+/-1.0 years) were studied. Women with osteopenia served as controls (group 1, n=30). Women with osteoporosis were randomly assigned to either risedronate 35 mg once weekly (group 2, n=21) or teriparatide 20 microg once daily (group 3, n=23) for six months. Blood samples for serum RANKL, OPG, N-terminal propeptide of type 1 collagen (P1NP), and C-terminal telopeptide of type 1 collagen (CTx) were obtained before treatment and three and six months after treatment. P1NP and CTx levels remained unchanged in group 1, decreased in group 2 (p<0.001), and increased in group 3 women (p<0.001) throughout the treatment. OPG levels remained unchanged while RANKL decreased gradually in all groups (p<0.001). There was no correlation between OPG or RANKL and P1NP or CTx. Our data suggest that neither antiresorptive nor osteoanabolic therapy causes specific alterations of serum OPG/RANKL levels; therefore, these cytokines cannot substitute for the established markers of bone turnover in the monitoring of response to osteoporosis treatment.
- Subjects :
- Aged
Biomarkers blood
Calcium blood
Collagen Type I blood
Etidronic Acid therapeutic use
Female
Humans
Middle Aged
Risedronic Acid
Bone Density Conservation Agents therapeutic use
Etidronic Acid analogs & derivatives
Osteoporosis, Postmenopausal blood
Osteoporosis, Postmenopausal drug therapy
Osteoprotegerin blood
RANK Ligand blood
Teriparatide therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0018-5043
- Volume :
- 40
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
- Publication Type :
- Academic Journal
- Accession number :
- 18275008
- Full Text :
- https://doi.org/10.1055/s-2008-1046787